[BMS354825] Correlation of Clinical Response to BMS-354825 with BCR-ABL Mutation Status in Imatinib-Resistant Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Associated Acute Lymphoblastic Leukemia (Ph+ ALL).

[Rob]

Background: Relapse of CML on imatinib is most often associated with point mutations in the BCR-ABL kinase domain. BMS-354825 is a novel ABL kinase inhibitor with = 300-fold greater potency than imatinib and preclinical activity against 14 of 15 imatinib resistant BCR-ABL mutants tested. Unlike imatinib, BMS-354825 binds the ABL kinase domain in both active and inactive conformations, and is thus predicted to have significant activity in most imatinib-resistant CML and Ph+ ALL cases.

 

http://cmlsupport.blogspot.com/2005/06/correlation-of-clinical-response-to.html